MIRA INFORM REPORT

 

 

Report Date :

11.10.2011

 

IDENTIFICATION DETAILS

 

Name :                                

HARMAN FINOCHEM LIMITED

 

 

Registered Office :

107-A, Vinay Bhavya Complex, 159 A CST Road, Kalina Santacruz (East), Mumbai – 400 098, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2010

 

 

Date of Incorporation :

17.03.1983

 

 

Com. Reg. No.:

11-29560

 

 

Capital Investment / Paid-up Capital :

Rs.47.636 Millions

 

 

CIN No.:

[Company Identification No.]

U24110MH1983PLC029560

 

 

Legal Form :

A Closely Held Public Limited Liability Company

 

 

Line of Business :

Manufacturing and Sale of Bulk Drugs and Pharmaceuticals

 

 

No. of Employees

Not Available

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (50)

 

RATING

STATUS

PROPOSED CREDIT LINE

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 3600000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company having satisfactory track. Trade relations are reported as fair. Business is active. Payments are reported to be regular and as per commitments.

 

The company can be considered normal for business dealings at usual trade terms and conditions.

 

NOTES:

 

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – April 1, 2010

 

Country Name

Previous Rating

(31.12.2009)

Current Rating

(01.04.2010)

India

A1

A1

 

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

LOCATIONS

 

Registered Office :

107-A, Vinay Bhavya Complex, 159 A CST Road, Kalina Santacruz (East), Mumbai – 400098, Maharashtra, India

Tel. No.:

91-22-26528080 / 67330100

Fax No.:

91-22-26528285

E-Mail :

harmanfinochem@vsnl.com

Info@harmanfinochem.com

Website :

http://www.harmanfinochem.com

 

 

DIRECTORS

 

As on 30.09.2010

 

Name :

Mr. Bhupinder Singh Manhas

Designation :

Managing Director

Address :

107-A, Vinaya Bhavya Complex, 159-A, CST Road, Kalina, Santacruz (East), Mumbai – 400 098, Maharashtra, India

Date of Birth/Age :

01.04.1950

Date of Appointment :

17.03.1983

DIN No.:

00121253

 

Other Directorship

 

S.No.

CIN

Name of the Company

Current designation of the director

Date of appointment at current designation

Original date of appointment

Company Status

Defaulting status

1

U24110MH1983PLC029560

Harman Finochem Limited

Managing director

17-03-83

17-03-83

Active

NO

2

U24230MH1989PTC132889

Well Worth Medicines Private Limited

Director

31-10-96

31-10-96

Active

NO

3

U30005MH1995PTC084585

Sanskar Info TV Private Limited

Additional director

08-09-10

08-09-10

Active

NO

 

 

 

Name :

Ms. Inderjeet Kaur Manhas

Designation :

Director

Address :

107-A, Vinaya Bhavya Complex, 159-A, CST Road, Kalina, Santacruz (East), Mumbai – 400 098, Maharashtra, India

Date of Birth/Age :

23.10.1951

Date of Appointment :

11.02.1997

DIN No.:

00121284

 


Other Directorship

 

S.No.

CIN

Name of the Company

Current designation of the director

Date of appointment at current designation

Original date of appointment

Company Status

Defaulting status

1

U24230MH1989PTC132889

Well Worth Medicines Private Limited

Director

15-07-96

15-07-96

Active

NO

2

U24110MH1983PLC029560

Harman Finochem Limited

Director

11-02-97

11-02-97

Active

NO

3

U25202MH1984PTC197665

Kirti Merchantile Private Limited

Director

02-01-06

02-01-06

Active

NO

 

 

 

Name :

Mr. Harpreet Singh Manhas

Designation :

Director

Address :

107-A, Vinaya Bhavya Complex, 159-A, CST Road, Kalina, Santacruz (East), Mumbai – 400 098, Maharashtra, India

Date of Birth/Age :

02.09.1976

Date of Appointment :

11.02.1997

DIN No.:

00121336

 

Other Directorship

 

S.No.

CIN

Name of the Company

Current designation of the director

Date of appointment at current designation

Original date of appointment

Company Status

Defaulting status

1

U24110MH1983PLC029560

Harman Finochem Limited

Director

11-02-97

11-02-97

Active

NO

2

U67120MH1995PTC095124

Laxmi Ramuna Investments Private Limited

Director

01-10-99

01-10-99

Active

NO

3

U24230MH1989PTC132889

Well Worth Medicines Private Limited

Director

24-08-01

24-08-01

Active

NO

4

U25202MH1984PTC197665

Kirti Merchantile Private Limited

Director

02-01-06

02-01-06

Active

NO

5

U99999MH1974PTC017240

Summerset Gardens Resort Private Limited

Additional director

24-11-10

24-11-10

Active

NO

 

 

 

Name :

Mr. Gurpreet Singh Bhupinder Singh Manhas

Designation :

Director

Address :

107-A, Vinaya Bhavya Complex, 159-A, CST Road, Kalina, Santacruz (East), Mumbai – 400 098, Maharashtra, India

Date of Birth/Age :

03.12.1979

Date of Appointment :

30.09.2008

DIN No.:

01885368

 

Other Directorship

 

S.No.

CIN

Name of the Company

Current designation of the director

Date of appointment at current designation

Original date of appointment

Company Status

Defaulting status

1

U24110MH1983PLC029560

Harman Finochem Limited

Director

30-09-08

15-10-07

Active

NO

2

U99999MH1974PTC017240

Summerset Gardens Resort Private Limited

Additional director

24-11-10

24-11-10

Active

NO

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

As on 30.09.2010

 

Names of Shareholders

 

No. of Shares

Bhupinder Singh Manhas

 

1935690

Bhupinder Singh Manhas (HUF)

 

118800

Harpreet Singh Manhas

 

390195

Gurpreet Singh Manhas

 

699855

Inderjeet Kaur Manhas

 

900000

Shyamsunder Shenoy

 

30

Unnikrishnan Parakkat

 

30

Wellworth Medicines Private Limited, India

 

690000

Kirti Mercantile Private Limited, India

 

29000

Total

 

4763600

 

As on 30.09.2010

 

Category

 

Percentage

Directors or relatives of directors

 

84.91

Other top fifty shareholders

 

15.09

Total

 

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturing and Sale of Bulk Drugs and Pharmaceuticals

 

 


PRODUCTION STATUS AS ON 31.03.2010

 

Particulars

Unit

Installed Capacity

Riboflavin Phosphate Sodium

MT

24

Dexamethasone Phosphate Sodium

KG

120

Betamethasone Phosphate Sodium

KG

120

Betamethasone Valerate

KG

120

Metformine Hydrochloride B.P.

MT

240

Riboflavine (Vitamine B2)

MT

5

Phenobarbitone

MT

60

Phenobarbitone Sodium

MT

20

Allopurinol

MT

240

Dimethylamine

MT

1000

 

Particulars

Actual Production

Allopurinol

290190

Carisoprodol

5922.3

Divalproex Sodium

2770.7

Fenofibrate

1602

Glimepiride

1.75

Glycopyrrolate

34.965

Ketamine Hydrochloride

--

Lamitrigine

2

Metformin Hydrochloride

2207913.2

Methadone Hydrochloride

430

Methyl Phenobarbital

583.15

Methylphenidate hydrochloride

6.8

Meprobamate

12660

Oxybutinin Hydrochloride

185.62

Oxiconazole Nitrate

110.5

Phenobarbitone

40345

Phenytain sodium usp

7137.8

Phenobarbitone Sodium I.P.

399.17

Phenytoin Base EP/USP

1250

Riboflavine Phosphate Sodium-

12344

Sodium Metal

--

Valporic Acid

1

Waste Solvent

57060

Xipamide

1000

 

 

GENERAL INFORMATION

 

No. of Employees

Not Available

 

 

Bankers :

·         Allahabad Bank

Industrial Finance Branch, Mumbai Samachar Marg, Fort, Mumbai – 400 023, Maharashtra, India

 

·         Kotak Mahindra Bank Limited

 

 

Facilities :

Secured Loans

As on 31.03.2010

Rs. in millions

As on 31.03.2009

Rs. in millions

Kotak Mahindra Bank Limited

(Against Hypothecation of Vehicles)

0.000

2.442

Total

0.000

2.442

 

 

Unsecured Loans

As on 31.03.2010

Rs. in millions

As on 31.03.2009

Rs. in millions

Incentive Loan on S. Tax

0.375

0.375

Total

0.375

0.375

 

Banking Relations :

--

 

 

Auditors :

 

Name :

K U Kothari and Company

Chartered Accountants

Address :

A-1/205, Laram Centre, S V Road, Andheri (West), Mumbai – 400 058, Maharashtra, India

Tel. No.:

91-22-26204773 / 26704183

E-Mail :

kukothari@rediffmail.com

 

 

Subsidiaries :

Well Worth Medicines Private limited

CIN No.: U24230MH1989PTC132889

 

 

CAPITAL STRUCTURE

 

As on 30.09.2010

 

Authorised Capital :

No. of Shares

Type

Value

Amount

5000000

Equity Shares

Rs.10/- each

Rs.50.000 Millions

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

4763600

Equity Shares

Rs.10/- each

Rs.47.636 Millions

 

 

 

 

 

 

 

 

 

 

 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2010

31.03.2009

31.03.2008

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

47.636

47.636

47.636

2] Share Application Money

0.000

0.000

0.000

3] Reserves & Surplus

864.338

608.370

458.709

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

911.974

656.006

506.345

LOAN FUNDS

 

 

 

1] Secured Loans

0.000

2.442

5.385

2] Unsecured Loans

0.375

0.375

1.470

TOTAL BORROWING

0.375

2.817

6.855

DEFERRED TAX LIABILITIES

0.000

0.000

0.000

 

 

 

 

TOTAL

912.349

658.823

513.200

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

579.391

310.870

277.692

Capital work-in-progress

0.000

0.000

0.000

 

 

 

 

INVESTMENT

18.286

18.918

75.662

DEFERREX TAX ASSETS

5.363

4.007

2.417

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

37.310
38.467
27.213

 

Sundry Debtors

209.811
178.611
133.946

 

Cash & Bank Balances

74.735
73.401
29.647

 

Other Current Assets

43.941
143.760
10.939

 

Loans & Advances

464.675
297.675
229.434

Total Current Assets

830.472
731.914

431.179

Less : CURRENT LIABILITIES & PROVISIONS

 

Sundry Creditors

109.959
135.122

95.781

 

Other Current Liabilities

 
 

 

 

Provisions

411.204
271.764

177.969

Total Current Liabilities

521.163
406.886

273.750

Net Current Assets

309.309
325.028

157.429

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.000

0.000

 

 

 

 

TOTAL

912.349

658.823

513.200

 

 


PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

 

31.03.2010

31.03.2009

31.03.2008

 

SALES

 

 

 

 

 

Sales

1314.344

1075.815

768.201

 

 

Other Income

7.989

49.447

27.807

 

 

TOTAL                                     (A)

1322.333

1125.262

796.008

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Consumption of raw material

535.804

536.386

366.457

 

 

Chemicals, Fuel, Consumable and Stores

51.802

52.616

27.685

 

 

Manufacture expenses

173.760

140.755

110.728

 

 

Administrative Expenses

40.436

47.705

36.843

 

 

Selling expenses

32.824

37.962

23.879

 

 

Directors Remuneration

19.800

19.800

16.225

 

 

Auditors Remuneration

0.441

0.441

0.337

 

 

Increase / (Decrease) in Stock

5.357

(3.363)

2.491

 

 

TOTAL                                     (B)

860.224

832.302

584.645

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)      (C)

462.109

292.960

211.363

 

 

 

 

 

Less

FINANCE COST                                                (D)

7.052

5.854

4.915

 

 

 

 

 

 

PROFIT BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                       (E)

455.057

287.106

206.448

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                     (F)

53.890

45.626

36.834

 

 

 

 

 

 

PROFIT BEFORE TAX (E-F)                               (G)

401.167

241.480

169.614

 

 

 

 

 

Less

TAX                                                                  (H)

136.866

83.459

56.801

 

 

 

 

 

 

PROFIT AFTER TAX (G-H)                                (I)

264.301

158.021

112.813

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

0.000

0.000

0.000

 

 

 

 

 

Less

APPROPRIATIONS

 

 

 

 

 

Dividend

7.145

7.145

9.527

 

 

Tax on Dividend

1.187

1.214

1.619

 

BALANCE CARRIED TO THE B/S

255.969

149.662

101.667

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

793.090

694.169

512.641

 

 

 

 

 

 

IMPORTS

 

 

 

 

Raw Material

354.038

241.076

NA

 

Capital Goods

6.513

12.722

NA

 

TOTAL IMPORTS

360.551

253.798

NA

 

 

 

 

 

 

Earnings Per Share (Rs.)

55.48

33.17

--

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2010

31.03.2009

31.03.2008

PAT / Total Income

(%)

19.99
14.04
14.17

 

 

 
 
 

Net Profit Margin

(PBT/Sales)

(%)

30.52
22.45
22.08

 

 

 
 
 

Return on Total Assets

(PBT/Total Assets}

(%)

28.45
23.16
23.93

 

 

 
 
 

Return on Investment (ROI)

(PBT/Networth)

 

0.44
0.37
0.33

 

 

 
 
 

Debt Equity Ratio

(Total Liability/Networth)

 

0.57
0.62
0.55

 

 

 
 
 

Current Ratio

(Current Asset/Current Liability)

 

1.59
1.80
1.58

 

 

LOCAL AGENCY FURTHER INFORMATION

 

BUSINESS

 

During the year the company has rendered the effected sales to the tune of Rs.1314.344 Millions as against the previous year figure of Rs.1075.815 Millions. The company has earned profit before taxation worth Rs.401.167 Millions as against the previous year profit Rs.241.480 Millions.

 

Bankers Charges Report as per Registry

 

This form is for

Modification of charge

Charge identification number of the modified 

90239691

Corporate identity number of the company

U24110MH1983PLC029560

Name of the company

HARMAN FINOCHEM PRIVATE LIMITED

Address of the registered office or of the principal place of  business in India of the company

107-A, Vinay Bhavya Complex, 159 A CST Road, Kalina Santacruz (East), Mumbai – 400098, Maharashtra, India

Type of charge

Immovable Property

Particular of charge holder

Allahabad Bank

Industrial Finance Branch, Mumbai Samachar Marg, Fort, Mumbai – 400023, Maharashtra, India

mumifb@allahabadbank.co.in

Nature of description of the instrument creating or modifying the charge

Supplemental Letter of Mortgagor Confirming Deposit of Title Deeds

Date of instrument Creating the charge

10.08.2007

Amount secured by the charge

Rs.90.000 Millions

Brief particulars of the principal terms an conditions and extent and operation of the charge

Rate of Interest

CC and PC – PLR plus 3 % p.a. shall be charged

FBN/FB, ILC/FLC and Bank Guarantee – As per the Bank’s circularized Instructions

 

Terms of Repayment

Repayment on Demand

 

Margin

CASH CREDIT – 25 % on Stocks (Fully paid for) and 30 % Book Debts and older than 90 days

FBN/FBP – Nil

ILC/FLC – 10 %

Bank Guarantee – 10 %

 

Extent and Operation of the charge

Exclusive first charge by way of Equitable Mortgage on immovable properties

 

Others

Limits enhanced from Rs.50.000 Millions to Rs.90.000 Millions

Short particulars of the property charged

Equitable Mortgage on Company’s immovable properties bearing Plot No. E-9 situated at Chikalthana Industrial Area, Village Mhanadpur, Taluka and Sub District and District Aurangabad admeasuring 8306 sq. mtrs.

Date of latest modification prior to the present modification

04.03.2005

Particulars of the present modification 

By present Modification Equitable Mortgage on Company’s Immovable properties situated at Chikalthana Industrial Area, Village Mhanadpur, District Aurangabad has now increased from Rs. 50.000 Millions to Rs. 90.000 Millions, to secure credit facilities detailed as under

 

Facilities

Rs in Millions

 

 

CC/PC

20.000

FBN/FBP

(10.000)

ILC/FLC

70.000

Bank Guarantee

(10.000)

Total

90.000

 

 


CONTINGENT LIABILITIES (As on 31.03.2010)

 

The Contingent Liability is Rs.26.200 Millions. 

 

FIXED ASSETS

 

·         Land

·         Factory Building

·         Flat and Staff Quarters

·         Office Equipment

·         Plant and Machinery

·         Electrical Fitting

·         Furniture and Fitting

·         Motor Car, Bus and Cycle

·         Computers

·         Office Premises

 

WEB DETAILS

 

PROFILE

Subject is a professionally managed independent company engaged in manufacturing of Active Pharmaceutical ingredients (API's) and chemical intermediates.

The company was established way back in 1983 by Bhupinder Singh Manhas, the CMD of the company.

·         Manufacture and Exporter of Active Pharmaceutical ingredients.

·         Two manufacturing sites at Aurangabad and one at Vapi with capacity of 350,000 Litres.

·         Supply of API’s as a Major Thrust Area to pharma and generic companies.

·         Certificate of recognition as “EXPORT HOUSE” by Government of India.

·         State-of-the art manufacturing facilities inspected and complying with cGMP norms as per USFDA, ICH Q7A, TGA, PIC, WHO-GMP, Schedule M and Japanese Foreign Accreditation.

·         State-of-the-art Quality Control Laboratories with GLP compliance.

·         cGMP compliance Pilot plant with clean room facility.

·         Powder processing area with pneumatic controls and Particle Size options: Milling and Micronising.

·         CRAMs offered.

·         State-of-the-art R and D center coming up 4th quarter 2009 in Navi-Mumbai.

 


 

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No records exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                              None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.49.07

UK Pound

1

Rs.76.65

Euro

1

Rs.66.17

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

5

PAID-UP CAPITAL

1~10

5

OPERATING SCALE

1~10

5

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

6

--PROFITABILIRY

1~10

6

--LIQUIDITY

1~10

6

--LEVERAGE

1~10

5

--RESERVES

1~10

6

--CREDIT LINES

1~10

6

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

TOTAL

 

50

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

-

NB

                                       New Business

-

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.